NCT07897669
A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Start date changed from estimate of Oct 21, 2026 to Nov 4, 2026
- Study sites: 0 to 1
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Distribution of First-Line Treatment Regimens by Predominant Histology
Timeframe: Up to 2 Years
Secondary (2)
Real world Progression Free Survival (rwPFS)
Real world Overall Tumor Response (rwOTR)
Arms and interventions
la/mBC
Patients with Locally Advanced or Metastatic Bladder Carcinoma (la/mBC) who received first line treatment.
Sites
1 site in 1 country
- Pfizer New YorkNew York, New York, United States